Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report)’s stock price traded down 28.6% during trading on Friday . The company traded as low as C$0.03 and last traded at C$0.03. 321,428 shares changed hands during mid-day trading, an increase of 60% from the average session volume of 201,068 shares. The stock had previously closed at C$0.04.
Aequus Pharmaceuticals Stock Performance
The company has a quick ratio of 0.46, a current ratio of 0.09 and a debt-to-equity ratio of 138.88. The stock has a market cap of C$3.98 million, a P/E ratio of -1.25 and a beta of 0.17. The firm’s 50-day moving average is C$0.02 and its two-hundred day moving average is C$0.02.
Aequus Pharmaceuticals (CVE:AQS – Get Free Report) last released its quarterly earnings data on Monday, April 29th. The company reported C($0.01) earnings per share (EPS) for the quarter. The company had revenue of C$0.05 million for the quarter. As a group, research analysts expect that Aequus Pharmaceuticals Inc. will post -0.1 EPS for the current year.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Featured Articles
- Five stocks we like better than Aequus Pharmaceuticals
- What is a Low P/E Ratio and What Does it Tell Investors?
- Top 3 Beverage Stocks: Summer Earnings Reveal Key Trends
- How to invest in blue chip stocks
- This Financial Stock’s Earnings Signal a Buying Opportunity
- What Are Dividend Achievers? An Introduction
- Social Platform Stock Hits New Highs: Is More Growth Ahead?
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
